Xcout Intel
1STBIO
1STBIO is a South Korea-based biotherapeutics company utilizing a proprietary AI-based drug discovery platform and genomic-based target discovery to enhance R&D efficiency. The firm is dedicated to discovering and developing novel therapeutics for areas of significant unmet medical need with a small team of 29 employees.
Subscribe to see 1STBIO’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
1STBIO at a glance
1STBIO is a biotechnology company headquartered in South Korea. Its most recent funding round, Series D, raised $23.5M in January 2026. Xcout tracks 10 named people at 1STBIO, including Kim Jae-eun (CEO).
1STBIO leadership
- Kim Jae-eunCEO
- Sungkyu LeeExecutive Vice President, Chief Operating Officer
- Brian YoungHoon KimChief Financial Officer
- Seongkon KimExecutive Vice President, Chief Technology Officer
- David KimChief Business Officer
- Jinhwa LeeExecutive Vice President, Chief Scientific Officer
4 more named people on record for 1STBIO, with roles, board committees and tenure — see the full roster →
1STBIO funding rounds
Every round on record:
| Date | Round | Amount | Investors |
|---|---|---|---|
| Series D | $23.5M | 14 named |
Who invested in each round, lead investors, valuations and the co-investor graph — open the full funding history →
Investors
1STBIO competitors
A few of 1STBIO's closest competitors — see the full list of competitors and alternatives →
Pharos iBio Co., Ltd. is a South Korean biotechnology company that uses artificial intelligence and big-data approaches for drug discovery and development. Its pipeline includes oncology candidates such as PHI-101, a FLT3 inhibitor being developed for acute myeloid leukemia and other cancers, serving patients with difficult-to-treat diseases and pharmaceutical development partners.
Spark Biopharma is headquartered in Seoul, South Korea, and focuses on discovering and providing small-molecule therapeutics using phenotypic discovery platforms to improve human health.
Y-Biologics is a South Korea-based research and development biotechnology company headquartered in Daejeon. The firm focuses on developing novel antibody-based therapeutics using its proprietary platform technologies and pipelines.
LigaChem Biosciences is a clinical-stage biopharmaceutical company headquartered in Daejeon, South Korea. The company specializes in the discovery and development of novel therapeutics utilizing proprietary technology platforms such as antibody-drug conjugates. With decades of dedicated drug development experience, it drives global healthcare innovation through open collaboration.
Get 1STBIO's news by email
Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.
Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →
Share this card
Post the link and the card appears automatically — each network fetches the image itself.
More on 1STBIO in Xcout Intel
- 10 named people with titles, LinkedIn and board committees
- 1 funding round with the investors in each, and who they co-invest with
- The full competitor set, tracking, exports and API access